Recent advances in oncolytic virus combined immunotherapy in tumor treatment

Area of Science:

• Oncology
• Virology
• Immunotherapy

Background:

• Oncolytic viruses (OVs) are emerging therapeutics with high replication efficiency and tumor-killing effects.
• OV monotherapy has limitations, prompting research into combination strategies.
• Immunotherapy combined with OVs shows significant promise in preclinical and clinical settings.

Purpose of the Study:

• To systematically review the latest advancements in combining oncolytic viruses with various immunotherapies for cancer treatment.
• To highlight future directions and potential of these combination strategies for enhanced clinical application.

Main Methods:

• Review of recent scientific literature on oncolytic virus and immunotherapy combinations.
• Analysis of preclinical and clinical trial data.
• Synthesis of information on novel immunotherapy approaches used in conjunction with OVs.

Main Results:

• Combination therapy, particularly with immunotherapies like cellular immunotherapy, immune checkpoint inhibitors, and cancer vaccines, yields improved tumor eradication.
• Genetic engineering advancements facilitate the development of sophisticated OV-immunotherapy combinations.
• These combined strategies have demonstrated enhanced clinical outcomes and improved patient quality of life.

Conclusions:

• Combining oncolytic viruses with immunotherapy represents a powerful strategy for advancing cancer treatment.
• Future research should focus on optimizing these combination strategies to maximize clinical efficacy.
• This approach holds significant potential for promoting the broader clinical application of oncolytic viruses in oncology.